Key facts
- Notable investors include U-Tao Investment.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Origin Reconstruction
- ·The full record, as it builds
Funding rounds
No funding rounds for Origin Reconstruction are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Origin Reconstruction
Developer of a biotechnology research and development platform designed for synthetic biology and industrial fermentation applications. The company's platform offers enzyme development, microbial strain optimization, and cell technology integration with laboratory-scale validation and modular scalability, enabling biotechnology and chemical production sectors to enhance process efficiency and support the creation of novel bio-based materials.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Origin Reconstruction doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Origin Reconstruction shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Origin Reconstruction in its N-PORT filings yet. We sweep new filings monthly.